The genitourinary syndrome of menopause (GSM) is a new term that describes various menopausal symptoms and signs including not only genital symptoms (dryness, burning, and irritation), and sexual symptoms (lack of lubrication, discomfort or pain, and impaired function, but also urinary symptoms (urgency, dysuria, and recurrent urinary tract infections). The terms vulvovaginal atrophy and atrophic vaginitis, which were generally used until recently, had a limitation because they did not cover the full spectrum of symptoms and did not imply that the symptoms are related to a decreased estrogen level in menopause. Since the GSM may have a profound negative impact on the quality of life of postmenopausal women, women should be made aware of these problems and treated with an appropriate effective therapy. Thus, in this review we introduce new terminology and discuss the importance of comprehension of GSM and the necessity of active treatment of this syndrome in postmenopausal women. 
Introduction
The genitourinary syndrome of menopause (GSM) is a new term that describes various menopausal symptoms and signs associated with physical changes of the vulva, vagina, and lower urinary tract. The GSM includes not only genital symptoms (dryness, burning, and irritation) and sexual symptoms (lack of lubrication, discomfort or pain, and impaired function), but also urinary symptoms (urgency, dysuria, and recurrent urinary tract infections [UTI]) ( Table 1) . 1 The terms vulvovaginal atrophy and atrophic vaginitis were widely used until recently, but they have been considered to be inadequate for referring to the constellation of symptoms and signs associated with the genitourinary system after menopause. The term vulvovaginal atrophy mentions the vulva and vagina only, and these words are not used comfortably in general social discussion and in the media. The term atrophic vaginitis implies a state of inflammation or infection, which is not a primary component of menopausal changes. In addition, a limitation of the terms vulvovaginal atrophy and atrophic vaginitis is that they do not take into account the symptoms of the lower urinary tract, which are among the most important symptoms related to menopause. 
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In this review, we introduce the new terminology and discuss the importance of comprehension of GSM and its active treatment in postmenopausal women.
Prevalence of GSM 
Lower urinary tract dysfunction
The female genital tract and lower urinary tract share a common embryonic origin, both arising from the urogenital sinus. 10 As estrogen plays an important role in the function of the lower urinary tract throughout the premenopausal period, estrogen deficiency after menopause causes lower urinary tract symptoms, such as dysuria, urgency, frequency, nocturia, urinary incontinence (UI), and recurrent UTI. 10 In a study by Robinson and Cardozo, 10 about 20% of had stress UI (SUI). In particular, urge UI is more prevalent after menopause than before menopause, and its prevalence increases with time in women with estrogen deficiency.
Since ERs are present in the trigone of the bladder and in the squamous epithelium of both the proximal and distal urethra, estrogen may increase the sensory threshold of the bladder and urethral closure pressure. 10 The study by Hyun et al. 11 suggested that the major cause of UI in postmenopausal women was the intrinsic sphincteric dysfunction related to altered connective tissue following estrogen deficiency, while the anatomical change was the most responsible factor of UI in premenopausal women. 
GSM and Quality of Life (QOL)
The Korean postmenopausal population was 5.26 million in 2000 (22.5% of total female population). In 2030, the postmenopausal population will be 13.15 million, comprising nearly half of the entire female population. 15 Therefore, appropriate care of these postmenopausal women will be one of the most important issues in our society. Since the genitourinary symptoms related to an abrupt menopause in these patients tend to present in relatively younger women and cause greater sexual dysfunction and poorer QOL outcomes, the management of their menopausal symptoms has become an increasingly important issue.
Treatment of GSM
The primary goal of treating GSM is to relieve symptoms. 36 In addition, the serum estradiol levels remained within the normal postmenopausal level and endometrial hyperplasia or adenocarcinoma was extremely rare. 32 Although vaginal estrogen therapy is generally safe for most symptomatic women with GSM, the treatment is contraindicated in some women with undiagnosed vaginal or uterine bleeding and controversial in women with estrogendependent neoplasia (e.g., breast cancer or endometrial cancer). 18 
Conclusion
The GSM is a comprehensive term that includes vulvovaginal symptoms and lower urinary tract symptoms related to low estrogen levels. The terms vulvovaginal atrophy and atrophic vaginitis, which were in general use until recently, had a limitation because they did not cover the full spectrum of symptoms and did not imply that the symptoms were related to decreased estrogen levels in menopausal state. Actually, only a few women attributed symptoms to menopause or hormonal changes, most women do not consult a gynecologist about their symptoms, considering them to be part of normal aging. 37 Also a number of women are still unwilling to take HT due to the concern of adverse effects including cancer. J MM
